The full name of Epclusa and the introduction and applicable analysis of different versions of the drug

The full name of Epclusa (Chinese trade name "Epclusa") is Sofosbuvir/Velpatasvir tablets (Sofosbuvir/Velpatasvir), produced by Gilead (Gilead Sciences), it is an oral, fully oral direct antiviral drug (DAA). Its biggest feature is that it is a "pan-genotypic" hepatitis C treatment drug, that is, no matter which genotype of hepatitis C virus (1-6type) the patient is infected with, it can exert a good therapeutic effect. Therefore, it has extremely wide coverage in clinical application and is called the "first-line treatment option for hepatitis C."

There are multiple versions of Jisandai in different countries and regions. The original drug Epclusa is commonly used in the United States, Europe and some Asian countries, with the most sufficient efficacy and safety data and a relatively high price. Countries such as India and Bangladesh have produced more affordable versions of generic drugs. For example, India's Mylan, Natco, Hetero and other pharmaceutical companies have legally authorized generic drugs. Their ingredients and dosage are the same as the original drugs, and they can achieve similar cure rates. Mainland China introduced the original drug Bintongsa in 2018 , and it was included in the national medical insurance directory in 2019 , which greatly improved patient accessibility.

From the perspective of the applicable population, Jisandai is suitable for adult patients with chronic hepatitis C, regardless of whether they are accompanied by compensated cirrhosis. For some patients who have failed previous treatments or have decompensated cirrhosis, they usually need to be used in combination with ribavirin under the guidance of a doctor to enhance the efficacy. Clinical data shows that the cure rate (SVR12, i.e. sustained virological response rate) of G3S can reach more than 95%, which also makes it one of the first choices for the treatment of hepatitis C worldwide. The medication cycle is usually 12 weeks, and it can be adjusted according to the situation of some special patients.

In general, Jisandai (Epclusa/Epclusa) brings hope of cure to hepatitis C patients with its characteristics of "pan-genotype, short treatment course, high efficacy and good safety". For patients, the choice between original drugs or generic drugs often depends on economic conditions and purchasing channels. If in mainland China, the original drugs after medical insurance are already very cost-effective; if through overseas channels, Indian generic drugs may be more in line with the paying ability of some patients. No matter which version you choose, you should use the medication rationally under the guidance of a doctor to ensure efficacy and safety.

Reference materials:https://www.drugs.com/